TGTX

$61.63+1.45%visit website

TG THERAPEUTICS, INC.

Market Cap

$9.4B

Live price × SEC shares (Aug 3, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.86

60mo monthly vs SPY

P/E (TTM)

22.5

TTM to Jun 2026 · diluted EPS

P/S (TTM)

11.8

TTM to Jun 2026 · revenue

P/B

15.6

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

70.6

TTM to Jun 2026 · EV incl. net debt

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	161,709	192,574	204,918	240,335	799,536
Cost of revenue	28,093	38,142	33,510	41,194	140,939
Research & development	40,878	41,193	48,396	95,337	225,804
Selling, general & administrative	63,373	62,745	88,217	82,130	296,465
Operating income	29,365	50,494	34,795	21,674	136,328
Interest expense	6,721	6,533	7,666	16,572	37,492
Pretax income	25,909	45,093	20,363	10,234	101,599
Income tax	(364,986)	22,056	586	2,453	(339,891)
Net income	390,895	23,037	19,777	7,781	441,490
EPS (basic) ($)	2.69		0.14	0.05	3.06
EPS (diluted) ($)	2.43		0.12	0.05	2.74
Weighted avg. shares (basic)	145,417		144,439	141,770
Weighted avg. shares (diluted)	160,998		160,062	157,282

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 5, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 59 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

8 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Aug 3, 2026 accepted 7:05 AM ET	2.02Earnings release	Document SEC ↗
Jun 12, 2026 accepted 4:32 PM ET	5.07Shareholder vote	Document SEC ↗
Jun 3, 2026 accepted 7:34 AM ET	8.01Other events	Document SEC ↗
May 27, 2026 accepted 4:34 PM ET	8.01Other events	Document SEC ↗
May 6, 2026 accepted 7:25 AM ET	2.02Earnings release	Document SEC ↗
Mar 20, 2026 accepted 4:33 PM ET	1.01Material agreement2.03New debt obligation	Document SEC ↗
Feb 26, 2026 accepted 7:08 AM ET	2.02Earnings release	Document SEC ↗
Jan 13, 2026 accepted 4:27 PM ET	7.01Reg FD disclosure	Document SEC ↗
Nov 3, 2025 accepted 7:34 AM ET	2.02Earnings release	Document SEC ↗
Aug 4, 2025 accepted 7:35 AM ET	2.02Earnings release	Document SEC ↗